Psoriasis treatment

View All

cosentyx-for-hidradenitis-suppurativa-treatment
Novartis Cosentyx: First Biologic Hidradenitis Suppurativa Treatment After Almost Ten Years

While another inflammatory biologic is making strides in the hidradenitis suppurativa treatment domain, Cosentyx by Novartis currently holds a significant lead. This advantage is crucial for Swiss Pharma, especially as dermatology experts anticipate strong competition from UCB’s bimekizumab, recently approved as Bi...

Find More

emerging-drugs-for-plaque-psoriasis-treatment
What Does the Future of Plaque Psoriasis Treatment Market Look Like?

Psoriasis is a common skin condition that accelerates the life cycle of skin cells. More than 3% of the adult population in the United States suffers from psoriasis. That equates to more than 7.5 million US adults. According to the World Psoriasis Day Consortium, 125 million people worldwide (2-3% of the total popu...

Find More